



## UvA-DARE (Digital Academic Repository)

### Transfusion practices and novel blood products

*Pre-clinical and clinical studies*

de Bruin, S.

#### Publication date

2022

[Link to publication](#)

#### Citation for published version (APA):

de Bruin, S. (2022). *Transfusion practices and novel blood products: Pre-clinical and clinical studies*. [Thesis, fully internal, Universiteit van Amsterdam].

#### General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

#### Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.



# CHAPTER 2

## **Transfusion practice in the non-bleeding critically ill; an international online survey – The TRACE Survey**

Sanne de Bruin, Thomas W.L. Scheeren, Jan Bakker, Robin van Bruggen, Alexander P.J. Vlaar and on behalf of the Cardiovascular Dynamics Section and Transfusion Guideline Task Force of the ESICM

*Published Critical Care 2019: Volume 23, Issue 1, Page 309*

## Abstract

**Background:** Over the last decade multiple large randomized controlled trials have studied alternative transfusion strategies in critically ill patients, demonstrating the safety of restrictive transfusion strategies. Due to the lack of international guidelines specific for the intensive care unit (ICU), we hypothesized that a large heterogeneity in transfusion practice in this patient population exists. The aim of this study was to describe current transfusion practices and identify knowledge gaps.

**Methods:** An online, anonymous, worldwide survey among ICU physicians was performed evaluating red blood cell, platelet and plasma transfusion practices. Furthermore, the presence of a hospital or ICU specific transfusion guideline was asked. Only completed surveys were analysed.

**Results:** 947 respondents filled in the survey of which 725 could be analysed. Hospital transfusion protocol available in their ICU was reported by 53% of the respondents. Only 29% of respondents used an ICU specific transfusion guideline. The reported haemoglobin (Hb) threshold for the general ICU population was 7 g/dL (7-7). The highest reported variation in transfusion threshold was in patients on extracorporeal membrane oxygenation or with brain injury (8 g/dL (7.0-9.0)). Platelets were transfused at a median count of  $20 \times 10^9$  cells/L IQR (10-25) in asymptomatic patients, but at a higher count prior to invasive procedures ( $p < 0.001$ ). In patients with an international normalized ratio (INR)  $> 3$ , 43% and 57% of the respondents would consider plasma transfusion without any upcoming procedures or prior to a planned invasive procedure, respectively. Finally, doctors with base specialty anaesthesiology transfused critically ill patients more liberally compared to internal medicine physicians.

**Conclusion:** Red blood cell transfusion practice for the general ICU population is restrictive, while for different subpopulations higher Hb thresholds are applied. Furthermore, practice in plasma and platelet transfusion is heterogeneous and local transfusion guidelines are lacking in the majority of the ICUs.

## Introduction

As critically ill patients frequently develop anaemia, thrombocytopenia or coagulopathy<sup>1-3</sup>, transfusion of blood components is a frequent intervention in the intensive care unit (ICU). About 12.5% of all transfused red cell concentrates (RCCs), 13% of all platelet concentrates (PC) and 30% of all plasma units in the hospital are transfused in the ICU<sup>4</sup>. However these products are associated with life threatening adverse events including transfusion related acute lung injury (TRALI), transfusion associated cardiac overload (TACO), and transfusion related immunomodulation (TRIM)<sup>5-7</sup>.

Since the Transfusion Requirements in Critical Care (TRICC) trial, 20 years ago, it has been increasingly recognized that a restrictive RCC transfusion strategy may be as safe as a liberal strategy and even reduce patient mortality in specific patient subpopulations<sup>8</sup>. Consequently, ICU transfusion practice has shifted towards more restrictive strategies. From 2002 to 2012, the incidence of RCC transfusion in critically ill patients has dropped from 37%<sup>9</sup> to 26%<sup>1</sup> during ICU admission. This reduction coincided with the publication of multiple large international randomized controlled trials (RCTs) showing the safety of a restrictive transfusion strategy<sup>8,10,11</sup>.

While multiple large RCTs have been performed to compare liberal versus restrictive strategies in red blood cell transfusions in ICUs, RCTs studying the optimal transfusion strategies in critically ill patients for plasma and platelets are limited or had a small sample size<sup>12</sup>. It is difficult to judge what “appropriate” transfusion triggers are for these blood products. This uncertainty is reflected in poor adherence to recommended best practices. It is estimated that hospital wide 37% of transfused plasma units and 33% of transfused platelets are administered outside guideline recommendations<sup>13-15</sup>.

Of note there is no international ICU transfusion guideline. The aim of this survey was to evaluate the use of local transfusion guidelines in the ICU and the applied transfusion thresholds for RCC, PLT and plasma transfusion in ICU patients without an active haemorrhage.

## Methods

### Survey

An anonymous survey on transfusion practices in non-bleeding patients was conducted among intensivists, intensivist in training and non-intensivists specialists attending in

the intensive care medicine. This survey was initiated by the Cardiovascular Dynamics Section and endorsed by the European Society of Intensive Care Medicine (ESICM). In addition, multiple national intensive care societies distributed the survey to its members by newsletters and/or promoted it on their website (see Additional file 1 for contributors).

### ***Study design***

An online platform was used to set up the questionnaire (SurveyMonkey; Portland, OR, USA). After designing, the survey was tested by an international panel of intensivists to optimize the validity and accuracy of the questionnaire. The survey included 40 questions, divided into four sections, respondent demographics, transfusion practice regarding red blood cells (15-17 questions), platelets (5 questions) and plasma transfusions (8 questions, see Additional file 1 for static version). Multiple clinically relevant subpopulations (also non-bleeding) were addressed in each section. For red cell transfusion, first the preferred haemoglobin (Hb) threshold for the general ICU population was asked, followed by the preferred Hb level for each subpopulations. For platelet transfusion, a distinction was made between transfusion prophylactically and prior different invasive procedures. For plasma transfusions, a distinction was made between prophylactic transfusion without a planned procedure and prior to an invasive procedure in general.

### ***Statistical analysis***

Only completed surveys were analysed. Since some questions were not applicable for all doctors, respondents were allowed to leave specific questions about subgroups/specific interventions open. This missing data was not imputed.

Descriptive statistics were used to characterize the respondent demographics. Normal distributed and non-normal distributed data was reported as mean (standard deviation) or as median (first quartile-third quartile) respectively. Categorical data was presented as percentage. Participants were able to fill in Hb thresholds in g/dL, g/L, or mmol/L, and all answers were converted to g/dL for analysis.

Transfusion thresholds were not normally distributed, therefore the Kruskal-Wallis test was used to test whether the transfusion thresholds differed significantly subpopulations or between interventions. As post hoc test, the Dunn test with Bonferroni correction was used. In addition, transfusion thresholds were analysed using the Wilcoxon sum rank test or Kruskal-Wallis test to test the dependence of two grouping variables or more than 2 grouping variables respectively. Chi-square test with Yates's correction for continuity was used for categorical variables. For comparing different world regions,

only regions where at least ten respondents were working were taken into account because they may not accurately represent the transfusion practice across their region. All tests were two sided. A p-value <0.05 was considered to be statistically significant. Statistical tests were performed with R studio (2018, 3.5.1, Vienna).

## Results

### *Demographics*

The survey was open for 6 months (June 2018 to November 2018). Of the 947 received surveys, 769 were complete, of these 44 were excluded because the respondents did not fulfil study inclusion criteria (i.e. non-physician, or pediatric ICU physician). The remaining 725 completed surveys (representing 69 countries) were included in the study. The majority of the participants practiced ICU in Europe (76%) (Additional file 1, figure S1). Background specialties were mainly anaesthesiology (62%) and internal medicine (20%), other demographics are shown in table 1.

**Table.1 Respondents** demographics

<b>Demographics</b>	<b>No. of respondents (%)</b>
Certification level	
Intensivist	589 (81)
Resident, specialist in training	53 (7)
Specialist, non-intensivist practicing ICU	73 (10)
Other	10 (1)
Primary medical specialty	
Anaesthesiology	450 (62)
Cardiology	18 (2)
Internal medicine	144 (20)
Neurology	4 (1)
Pulmonology	25 (3)
Surgery	15 (2)
Other	67 (10)
Type of intensive care unit (ICU)	
Medical ICU	63 (9)
Surgical ICU	536 (74)
Mixed ICU	110 (15)
Other	16 (2)
Number of ICU beds	
<10	209 (29)

**Table.1 Respondents** demographics (*continued*)


<b>Demographics</b>	<b>No. of respondents (%)</b>
10-15	206 (28)
16-20	115 (16)
>20	193 (27)
Not specified	2 (0)
Annual number of patients treated in the ICU	
<500	178 (25)
501-1000	239 (33)
1001-1500	139 (19)
1501-2000	66 (9)
>2000	98 (14)
Not specified	5 (1)
Type of institution	
University hospital	326 (45)
University affiliated hospital	146 (20)
Non-university public hospital	183 (25)
Private hospital	64 (9)
Other	6 (1)
Which unit do you use to measure haemoglobin	
g/dL	499 (69)
g/L	171 (24)
mmol/L	55 (8)

### **Red cell transfusion**

The median reported Hb threshold used in the general ICU population was 7 g/dL (7.0-7.5). Higher Hb transfusion thresholds were reported in patients with acute coronary syndrome (ACS), septic shock, acute brain injury, those receiving extracorporeal membrane oxygenation (ECMO), with acute respiratory distress syndrome (ARDS), age over 65 years, and with prolonged weaning were transfused at higher Hb thresholds ( $p < 0.001$  for all patient populations, see figure 1). Thresholds did not differ between oncological/hematologic patients and the general ICU population ( $p=1$ ). The largest variation in transfusion thresholds was observed in patients on ECMO and in patients with traumatic brain injury. Respondents would transfuse these patient populations at a Hb threshold of 8.0 g/dL (7.0-9.0). The highest Hb threshold was reported for patients with ACS median 9.0 g/dL (8.0-9.7).

Following the transfusion of the first RCC, Hb levels were routinely not re-evaluated before transfusing a second unit. Of the respondents 28% always re-evaluate the Hb level while 16% never re-evaluate.





**Figure 1.** Respondents were asked which Hb threshold they used for RCC transfusion in the general ICU population and different subpopulations. Respondents used in the general population a Hb threshold of 7.0 g/dL (7.0-7.5). This is significantly lower ( $p < 0.001$ ) compared to patients with acute coronary syndrome (9.0 g/dL (8-9.7)), septic shock (7.5 g/dL (7.0-8.0)), acute brain injury (8.0 g/dL (7.0-9.0)), patients undergoing ECMO (8.0 (7.0-9.0) g/dL), issues of prolonged weaning (7.5 g/dL (7.0-8.0)), or patients with ARDS (7.5 g/dL (7.0-8.0)). No statistical differences were observed between the general ICU population and patients older than 65 years, patients with (haematological) oncology (all three groups were transfused at a Hb threshold of 7.0 g/dL (7.0-7.5)).

### Transfusion triggers


The majority of the respondents used clinical markers such as hypotension and tachycardia along with Hb levels to guide transfusion. Among the respondents only 13% never uses other physiological triggers in addition to a Hb threshold. Of interest, 27% of the respondents would always use other physiological triggers (figure 2A).

Tachycardia (66%), hypotension (55%) and lactate levels  $> 2$  mmol/L (51%) were mentioned most often (figure 2B), while significant ECG changes were ranked as most important physiological trigger.

### Prevention of RCC transfusion

Use of iron or iron in combination with erythropoietin (EPO) to improve erythropoiesis and prevent RCC transfusion was reported by for 41% and 17% of respondents, respectively. EPO was reported by 12% of the respondents as a monotherapy. A quarter of the respondents would never use these pharmacological agents for this purpose. Non-pharmacological blood conservation measures were less common in the ICU. Closed loop


blood sampling was the most common intervention (23%), followed by microtube sampling (13%). Computerized decision support was used by only 2% of the respondents



**Figure 2.** The use transfusion triggers in addition to a haemoglobin threshold.

### ***Platelet transfusion***

In non-bleeding patients undergoing an invasive procedure, respondents would transfuse patients at a platelet count of  $20 \times 10^9$  cells/L (10-25). Platelet concentrates were transfused at higher platelet counts prior an invasive procedure ( $p < 0.001$ ). Respondents would transfuse at a platelet count of  $40 \times 10^9$  cells/L (20-50) prior to central venous catheter (CVC) placement,  $50 \times 10^9$  cells/L (50-75) prior to tracheotomy,  $50 \times 10^9$  cells/L (50-80) prior to general surgery, and  $100 \times 10^9$  cells/L (70-100) prior to neurosurgery. When transfusing a PLT concentrate, 18% of the respondents never re-evaluate the platelet count before transfusing a second unit.



**Figure 3.** Platelet thresholds prophylactically without any planned invasive procedure and prophylactically prior to different procedures.

### Coagulopathy

The majority (87%) of the respondents transfuse their patients with fresh frozen plasma, only 9.5% reported to use pooled plasma to correct coagulopathy.

In non-bleeding patients who will not undergo an invasive procedure, an international normalized ratio (INR) > 3 is infrequently corrected. Only 7% would always correct a prolonged INR (Figure 4A.). Vitamin K is the most commonly mentioned therapeutic agent to correct the INR in these patients (85%), followed by plasma (43%) and prothrombin complex (35%) (Figure 4B).

More physicians would correct a INR >3 prior to an invasive procedure compared to patients who are not undergoing an invasive procedure ( $p < 0.0001$ ). Among the respondents, 31% would always correct a prolonged INR in this setting (Figure 4A). Also, prior to an invasive procedure, the majority (70%) most of the respondents would use vitamin K as a therapeutic option, followed by prothrombin complex (58%) and plasma (57%) (Figure 4C).

To diagnose coagulopathy, INR/Prothrombin time (99%), activated partial thromboplastin time (APTT, 97%) and fibrinogen level (94%) are widely available tests in the

ICU. Visco-elastic tests are less common, only in the minority of the hospitals rotational thromboelastometry (ROTEM, 31%) or thromboelastography (TEG, 18%) are available as diagnostic tool.

### ***Guideline***

Among the respondents, 29% have an ICU specific and 53% a (not ICU specific) transfusion guideline in their ICU. The availability of a guideline has limited effect on the transfusion practice. Only for the general ICU population the presence of a (not ICU) specific transfusion guideline was associated with a lower transfusion threshold ( $p=0.028$ , Additional file 1 table S3). For other ICU subpopulations, this association with RCC transfusion practice was not present (Additional file 1 table S2 and S3). Also, for platelet and plasma transfusion no association was found between the presence of a guideline and transfusion practice (Additional file 1 table S5 and S6).


### ***Background specialty***

To investigate whether the base specialty influences transfusion practices, only the groups anaesthesiology (69% of the respondents) and internal medicine (20% of the respondents) were sufficiently present to perform additional testing. For RCC, PC and plasma transfusion, an association was found between base specialty and transfusion practice. Overall, the base specialty anaesthesiology was associated with a more liberal transfusion practice compared to internal medicine. With the exception of patients with ACS and patients on ECMO, physicians with the base specialty anaesthesiology said to transfuse all subpopulations at significantly higher Hb thresholds. Furthermore, anaesthesiologists more often report the use of physiological triggers in addition to Hb levels in their decision to transfuse than internal medicine physicians ( $p=0.02$ , see Additional file 1 table S4). Also, thrombocytopenic patients are transfused at higher platelet counts prior CVC placement ( $p=0.002$ ) and prior to tracheotomy ( $p=0.007$ , Additional file 1 table S7) when treated by a physician with the base specialty anaesthesiology. For plasma transfusion, only in prophylactically transfusions a different practice was observed between these two base specialties. Physicians with base specialty anaesthesiology transfuse plasma prophylactically more frequently (Additional file 1, Figure S3).

### ***Regional differences***

In all world regions, a median Hb threshold of 7g/dL (7.7) was reported for the general ICU population. For different subpopulations, a greater variety was reported, especially in patients with ACS, traumatic brain injury, and patients receiving ECMO (Additional file 1a figure S2). In platelet transfusion some alignment exists for prophylactic platelet transfusion with a median applied platelet count prophylactically between 15 and 20

$\times 10^9$  cells/L for all world regions. However, prior to an invasive procedure more heterogeneity exist (Additional file 1 figure S4). Prior to general surgery the largest differences between regions was observed, in half of the regions the mean of the applied platelet threshold was  $50 \times 10^9$  cells/L while in Southern Asia and South-Eastern Asia a median platelet count of 72.5 and  $100 \times 10^9$  cells/L was applied, respectively. Lastly, also plasma transfusion practices differed between world regions (Additional file 1 figure S5). In Southern Europe only 17% would never correct a vitamin K induced INR  $>3$  in the absence of an invasive procedure, whereas in South-Eastern Asia 50% would never correct this INR.



**Figure 4.** More respondents would correct an vitamin K induced INR  $>3$  prior to an invasive procedure than in the absent of a procedure(4A). Both, in the absence of an invasive procedure (4B) and prior an invasive procedure (4C), the majority would correct this with vitamin K.

## Discussion

This is the largest survey on transfusion practice in non-bleeding critically ill patients among ICU physicians to date. The main findings of this study are: 1) a high Hb threshold variation between ICU subpopulations, 2) the platelet transfusion threshold prior to invasive procedures differs greatly between and within the procedures, 3) plasma is considered by a large number of physicians in non-bleeding patients even in the absence of an invasive procedure, 4) base specialty of physicians is associated with variation in transfusion practices and 5) worldwide, institutions lack local ICU specific transfusion guidelines.

The reported Hb threshold for the general ICU population in this survey is in line with the finding of the TRICC study, which demonstrated the safety of a restrictive transfusion strategy in the ICU population<sup>8</sup>. However, when looking at different patient subpopu-

lations, a greater variety of applied Hb thresholds was found. For the septic patients respondents reported a significantly higher Hb threshold compared to the general population, what deviates from current evidence supporting a restrictive transfusion strategy also in septic patients<sup>11</sup>. For patients with ACS, the higher preferred Hb threshold of 9 g/dL (8-9.6) is in accordance with the transfusion guideline from the National Institute for Health and Care Excellence (NICE, 2018), in which a Hb threshold (8-10 g/dL) for patients with symptomatic coronary disease is advised. Also, patients with traumatic brain injury were transfused at higher Hb thresholds since these patients may be more sensitive to anaemia induced cerebral hypoxia. However, evidence to justify this more liberal transfusion practice is limited. Multiple large RCTs are currently studying whether these patients benefit from a liberal transfusion strategy (ClinicalTrials.gov, NCT02968654 and NCT02981407).

This survey also showed a high variety in preferred Hb thresholds for patients with ARDS and patients on ECMO. Since the evidence for these subpopulations is limited it is expected to observe a high heterogeneity in transfusion practice. For ARDS patients it is hypothesized that the hypoxaemia should be compensated by increasing the oxygen carrying capacity of the circulating blood by transfusing at higher Hb thresholds. However, there is no solid evidence to support this practice, and the downside of allogenic blood transfusion is not taken into account in this reasoning.

The applied platelet threshold differed between patients with and without an upcoming invasive procedure. The majority of the respondents (72%) would transfuse non-bleeding critically ill patients at a platelet count of  $\leq 20 \times 10^9$  cells/L. The potential harm of platelet transfusion is supported by two recent RCTs, in which it was shown that prophylactically platelet transfusion might be particularly harmful in neonates<sup>16</sup> and in patients with a cerebrovascular accident<sup>17</sup>. These studies cannot be directly translated to the non-bleeding critically ill adult patients, but they do show that platelet transfusion is not an intervention without risk. Prior to invasive procedures physicians transfuse platelets at higher platelet counts, while the evidence for this is limited. A meta-analysis has shown that complications prior to CVC placement in patients with coagulopathy, including thrombocytopenia and prolonged INR and APTT, are rare<sup>18</sup>. Thus, the need for any platelet transfusion prior to this procedure is questionable. A large RCT studying the need of platelet transfusion prior CVC placement in severe thrombocytopenic patients is now recruiting<sup>19</sup>.

Multiple RCTs have failed to demonstrate beneficial effects of prophylactic plasma transfusion prior to an invasive procedure in critically ill patients with an prolonged INR<sup>12,20,21</sup>.

The finding of this survey that 57% and 43% of physicians would consider to transfuse plasma to correct the prolonged INR in patients who used vitamin K antagonists prior an invasive procedure or without a planned invasive procedure, respectively, is striking in the absence of evidence for this practice.

To our knowledge, the influence of base specialty of intensivists on transfusion practice has not been studied before. Our survey showed that doctors with a base specialty anaesthesiology transfuse more liberal than those with internal medicine as base specialty. It might be that doctors with an internal medicine background are more aware of the harmful side effects of blood products, alternatively, anesthesiologists may tend to treat patients at higher risk of bleeding, and these practices spill over into the ICU.

The strength of this survey is the large number of respondents. However, both the anonymous character of this survey and the origin of the respondents might have introduced a selection bias and limits therefore the worldwide generalizability of our findings. Theoretically, it is possible that multiple respondents are employed in the same hospital, however also within hospitals heterogeneity in transfusion practice may exist. Furthermore, the number of respondents who did receive this survey but did not fill it in is unknown. We cannot exclude that non-responders transfuse differently than the responders of this survey. It may be possible that physicians with more interest in transfusion practice and thus with more awareness of the possible side effects of transfusion are over presented in this survey. In addition, due to the study design it was not appropriate to perform multivariable analysis. As result, it was not possible to exclude the presence of confounding variables on the observed significant associations. And finally, as with any clinical practice survey, the reported transfusion practices might differ from actual transfusion practices. Ideally, these results are confirmed in a prospective cohort study.

## Conclusion

In conclusion, in the general non-bleeding ICU population, the reported RCC transfusion practice was rather restrictive, however, in certain subpopulations including the critically ill with septic shock, higher applied Hb thresholds were reported, which deviates from current evidence. For other subpopulations such as patients with ARDS and patients on ECMO well powered RCTs are needed. In addition, optimal platelet thresholds are currently controversial and more awareness is necessary for correct indications of plasma

transfusion in non-bleeding patients. Finally, a local transfusion guideline for critically ill patients is lacking in the majority of ICUs worldwide.




## References

1. Vincent J-L, Jaschinski U, Wittebole X, Lefrant J-Y, Jakob SM, Almekhlafi GA, et al. Worldwide audit of blood transfusion practice in critically ill patients. *Crit Care* [Internet]. 2018 Dec 19;22(1):102. Available from: <https://ccforum.biomedcentral.com/articles/10.1186/s13054-018-2018-9>
2. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. *Crit Care Med* [Internet]. 2002 Aug;30(8):1765–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2163790>
3. Walsh TS, Stanworth SJ, Prescott RJ, Lee RJ, Watson DM, Wyncoll D, et al. Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units. *Crit Care Med* [Internet]. 2010 Oct;38(10):1939–46. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20639745>
4. Whitaker BI, Rajbhandary S, Harris A. 2013 AABB Blood Survey Report. 2013;
5. Bolton-Maggs PHB. SHOT conference report 2016: serious hazards of transfusion - human factors continue to cause most transfusion-related incidents. *Transfus Med* [Internet]. 2016 Dec;26(6):401–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27995700>
6. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA, et al. Proceedings of a consensus conference: towards an understanding of TRALI. *Transfus Med Rev* [Internet]. 2005 Jan;19(1):2–31. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15830325>
7. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): An update. *Blood Rev*. 2007;21(6):327–48.
8. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care. *N Engl J Med* [Internet]. 1999 Feb 11;340(6):409–17. Available from: <http://www.nejm.org/doi/abs/10.1056/NEJM199902113400601>
9. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, et al. Anemia and blood transfusion in critically ill patients. *J Am Med Assoc* [Internet]. 2002;288(12):1499–507. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12243637>
10. Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C, et al. Transfusion Strategies for Acute Upper Gastrointestinal Bleeding. *N Engl J Med* [Internet]. 2013;368(1):11–21. Available from: <http://www.nejm.org/doi/10.1056/NEJMoa1211801>
11. Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. *N Engl J Med* [Internet]. 2014 Oct 9;371(15):1381–91. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25270275>
12. Müller MC, Arbous MS, Spoelstra-de Man AM, Vink R, Karakus A, Straat M, et al. Transfusion of fresh-frozen plasma in critically ill patients with a coagulopathy before invasive procedures: a randomized clinical trial (CME). *Transfusion* [Internet]. 2015 Jan;55(1):26–35; quiz 25. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24912653>
13. Schofield WN, Rubin GL, Dean MG. Appropriateness of platelet, fresh frozen plasma and cryoprecipitate transfusion in New South Wales public hospitals. *Med J Aust*. 2003;178(3):117–21.
14. Qureshi H, Lowe D, Dobson P, Grant-Casey J, Parris E, Dalton D, et al. National comparative audit of the use of platelet transfusions in the UK. *Transfus Clin Biol*. 2007;14(6):509–13.


15. Stanworth SJ, Walsh TS, Prescott RJ, Lee RJ, Watson DM, Wyncoll DLA. Thrombocytopenia and platelet transfusion in UK critical care: A multicenter observational study. *Transfusion*. 2013;53(5):1050–8.
16. Baharoglu MI, Cordonnier C, Salman RAS, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. *Lancet [Internet]*. 2016;387(10038):2605–13. Available from: [http://dx.doi.org/10.1016/S0140-6736\(16\)30392-0](http://dx.doi.org/10.1016/S0140-6736(16)30392-0)
17. Curley A, Stanworth SJ, Willoughby K, Fustolo-Gunnink SF, Venkatesh V, Hudson C, et al. Randomized Trial of Platelet-Transfusion Thresholds in Neonates. *N Engl J Med [Internet]*. 2019;380(3):242–51. Available from: <http://www.nejm.org/doi/10.1056/NEJMoa1807320>
18. van de Weerd EK, Peters AL, Goudswaard EJ, Binnekade JM, van Lienden KP, Biemond BJ, et al. The practice of platelet transfusion prior to central venous catheterization in presence of coagulopathy: a national survey among clinicians. *Vox Sang*. 2017;112(4):343–51.
19. van de Weerd EK, Biemond BJ, Zeerleder SS, van Lienden KP, Binnekade JM, Vlaar APJ, et al. Prophylactic platelet transfusion prior to central venous catheter placement in patients with thrombocytopenia: Study protocol for a randomised controlled trial. *Trials*. 2018;19(1):1–10.
20. Durila M, Lukáš P, Astravkhava M, Beroušek J, Zábrodský M, Vymazal T. Tracheostomy in intensive care unit patients can be performed without bleeding complications in case of normal thromboelastometry results (EXTEM CT) despite increased PT-INR: A prospective pilot study. *BMC Anesthesiol [Internet]*. 2015;15(1):1–6. Available from: <http://dx.doi.org/10.1186/s12871-015-0073-1>
21. Yang L, Stanworth S, Hopewell S, Doree C, Murphy M. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. *Transfusion [Internet]*. 2012 Aug;52(8):1673–86; quiz 1673. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22257164>

## Supplementary material


### *Supplemental Figures*




**Figure S1** Origin of respondents




**Figure S2.** Patients with acute coronary syndrome were transfused at highest Hb levels in South Eastern Asia with a median Hb level of 10 g/dL (8.75-10) while in Western Europe the median reported transfusion threshold was 8.1 g/dL (8-8.1). For patients with traumatic brain injury also respondents from South Eastern Asia reported the highest Hb levels as transfusion thresholds of 9.5 g/dL (8-9.5) and lowest Hb levels were reported in Northern America with a median Hb of 7 g/dL (7-7). In Southern Asia the highest Hb thresholds for patients receiving ECMO were reported with 9 g/dL (7-9), while the lowest Hb levels were reported by respondents working in Northern America with 7 g/dL (7-7).




**Figure S3.** The use of a physiological transfusion trigger in addition to a Hb threshold. Significant differences were observed for anaesthesiology versus internal medicine ( $p = 0.02$ ).



**Figure S4.** Regional differences of applied platelet thresholds prophylactically without any planned invasive procedure and prophylactically prior to different procedures



**Figure 55.** Regional differences of the correction of a vitamin K induced INR >3 (A) prophylactically in the absence of an invasive procedure and (B) prior to an invasive procedure



**Figure 56.** Effect of base specialty of ICU doctor on the correction of a vitamin K induced INR >3 (A) prophylactically in the absent of an invasive procedure ( $p=0.0272$ ) and (B) prior to an invasive procedure ( $p=0.03983$ ).

**Table S1**

<b>World region</b>	<b>n =</b>
Australia and New Zealand	11
Caribbean	1
Central America	8
Central Asia	1
Eastern Africa	2
Eastern Asia	4
Eastern Europe	53
Northern Africa	6
Northern America	16
Northern Europe	109
South-Eastern Asia	12
South America	38
Southern Africa	2
Southern Asia	26
Southern Europe	197
Western Asia	45
Western Europe	184

**Table S2**

	<b>ICU specific guideline</b>		
	<b>Available</b>	<b>Not available</b>	<b>p value</b>
<b>General ICU population</b>	7(7-7.5)	7(7-7.5)	0.1341
<b>Acute coronary syndrome</b>	9(8-9.7)	9(8-9.6)	0.1009
<b>Septic shock</b>	7.3(7-8)	7.5(7-8)	0.389
<b>Traumatic brain injury</b>	8(7-9)	8(7-9)	0.9795
<b>ECMO</b>	8(7-9)	8(7.5-9)	0.2455
<b>ARDS</b>	7(7-8)	7.5(7-8)	0.0517
<b>Prolonged weaning</b>	7.5(7-8)	7.4(7-8)	0.9892
<b>Age ≥65 years</b>	7(7-8)	7(7-8)	0.6015
<b>Haematological oncology</b>	7(7-8)	7(7-8)	0.2184
<b>Oncology</b>	7(7-8)	7(7-8)	0.8695

**Table S3**

	<b>(not-ICU specific) Guideline</b>		
	<b>Available</b>	<b>Not available</b>	<b>p value</b>
<b>General ICU population</b>	7(7-7.5)	7(7-7.9)	0.0283
<b>Acute coronary syndrome</b>	9(8-9.7)	9(8-9)	0.8161
<b>Septic shock</b>	7.3(7-8)	7.5(7-8)	0.2662
<b>Traumatic brain injury</b>	8(7-9)	8(7-9)	0.783
<b>ECMO</b>	8(7-9)	8(7-9)	0.2794



<b>ARDS</b>	7(7-8)	7.5(7-8)	0.262
<b>Prolonged weaning</b>	7.1(7-8)	7.5(7-8)	0.1283
<b>Age ≥65 years</b>	7(7-8)	7(7-8)	0.0649
<b>Haematological oncology</b>	7(7-8)	7(7-8)	0.3209
<b>Oncology</b>	7(7-8)	7(7-8)	0.191

**Table S4**

	<b>Main specialty</b>		
	<b>Anaesthesiology</b>	<b>Internal medicine</b>	<b>p value</b>
<b>General ICU population</b>	7(7-8)	7(7-7)	0.0452
<b>Acute coronary syndrome</b>	9(8-9.7)	9(8-9.9)	0.3662
<b>Septic shock</b>	8(7-8)	7(7-8)	< 0.001
<b>Traumatic brain injury</b>	8(7.8-9)	8(7-9)	0.036
<b>ECMO</b>	8(7.7-9)	8(7-9.5)	0.5545
<b>ARDS</b>	8(7-8.2)	7(7-8)	< 0.001
<b>Prolonged weaning</b>	8(7-8)	7(7-8)	< 0.001
<b>Age ≥65 years</b>	7.2(7-8)	7(7-7.7)	0.0003
<b>Haematological oncology</b>	7(7-8)	7(7-7.4)	0.0224
<b>Oncology</b>	7(7-8)	7(7-7.2)	0.0459

**Table S5**

	<b>ICU specific transfusion guideline</b>		
	<b>Available</b>	<b>Not available</b>	<b>p value</b>
<b>Prophylactic</b>	20(10-20)	20(10-30)	0.2827
<b>Prior to CVC placement</b>	30(20-50)	45(20-50)	0.1299
<b>Prior to tracheotomy</b>	50(50-70)	50(50-71)	0.7226
<b>Prior to general surgery</b>	50.5(50-93)	50(50-80)	0.8616
<b>Prior to neurosurgery</b>	100(67.5-100)	100(75-100)	0.3684

**Table S6**

	<b>(not-ICU specific) transfusion guideline</b>		
	<b>Available</b>	<b>Not available</b>	<b>p value</b>
<b>Prophylactic</b>	20(10-25)	20(10-30)	0.8973
<b>Prior to CVC placement</b>	45(20-50)	40(20-50)	0.5185
<b>Prior to tracheotomy</b>	50(50-71)	50(50-70)	0.1976
<b>Prior to general surgery</b>	50(50-80)	53(50-90)	0.4122
<b>Prior to neurosurgery</b>	100(70-100)	100(75-100)	0.1442

**Table S7**

	<b>Main specialty</b>		
	<b>Anaesthesiology</b>	<b>Internal medicine</b>	<b>p value</b>
	<b>Platelet count</b>	<b>Platelet count</b>	
<b>Prophylactic</b>	20(10-30)	10(10-20)	0.0052
<b>Prior to CVC placement</b>	48.5(20-50)	30(20-50)	0.0023
<b>Prior to tracheotomy</b>	50(50-80)	50(50-51)	0.0069
<b>Prior to general surgery</b>	51(50-80)	50(50-81)	0.3439
<b>Prior to neurosurgery</b>	100(75-100)	100(80-100)	0.9409

## Appendix 1: Overview collaborating societies

- Australian and New Zealand Intensive Care Society (ANZICS)
- Czech Society of Anaesthesiology, Resuscitation & Intensive Care (CSARIM)
- Hellenic Society of Intensive Care (HSIC)
- Societa Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva (SIAARTI)
- Intensive Care Society of Ireland (ICSI)
- Lebanese Critical Care Society (LCCS)
- Nederlandse Vereniging voor Intensive Care (NVIC)
- Serbian Association of Anaesthesiologists & Intensivits (SAAI)
- Slovenian Society of Intensive Medicine (SSIM)
- Swedish Society of Anaesthesiology & Intensive Care Medicine (SFAI)
- Swiss Society of Intensive Care Medicine (SGI-SSICM)
- Turkish Society of Anesthesiology and Reanimation (TARD)
- Intensive Care Society (ICS, United Kindom)

## Appendix 2: Static version questionnaire

### Demographics

1. **In which country do you work?**
2. **What is your intensive care certification level**
  - a. Intensivist
  - b. Resident, specialist in training
  - c. Specialist non intensivist practising ICU
  - d. Nurse
  - e. Student
  - f. Other, please specify
3. **What is your primary medical specialty**
  - a. Anaesthesiology
  - b. Cardiology
  - c. Internal medicine
  - d. Neurology
  - e. Paediatrics
  - f. Pulmonology
  - g. Surgery
  - h. Other, please specify
4. **Type of intensive care unit (ICU)**
  - a. Medical ICU
  - b. Surgical ICU
  - c. Mixed ICU
  - d. Other, please specify
5. **Number of ICU beds**
  - a. <10
  - b. 10-15
  - c. 16-20
  - d. >20
6. **Annual number of patients treated in the ICU**
  - a. <500
  - b. 500-1000
  - c. 1001-1500
  - d. 1501-2000
  - e. >2000
7. **Type of institution**
  - a. University hospital
  - b. University affiliated hospital
  - c. Non-university public hospital
  - d. Private hospital
  - e. Other, please specify
8. **Do you have a transfusion protocol in your hospital?**
  - a. Yes
  - b. No
  - c. I don't know
  - d. Other, please specify
9. **Do you have a transfusion protocol specific for the intensive care unit in your hospital?**
  - a. Yes
  - b. No
  - c. I don't know
  - d. Other, please specify

## Red blood cell transfusion

10. Which unit do you use to measure hemoglobin levels?
  - a. g/dL
  - b. g/L (=mg/ml)
  - c. mmol/L
11. What is your overall threshold for blood transfusion in a general population of anemic critically ill patients?
12. What is your threshold for blood transfusion in anemic critically ill patients with acute coronary syndrome?
13. What is your threshold for blood transfusion in anemic critically ill patients with septic shock?
14. What is your threshold for blood transfusion in anemic critically ill patients with traumatic brain injury?
15. What is your threshold for blood transfusion in anemic critically ill patients receiving ECMO?
16. What is your threshold for blood transfusion in anemic critically ill patients with ARDS?
17. What is your threshold for blood transfusion in anemic critically ill patients with prolonged weaning from mechanical ventilation?
18. What is your threshold for blood transfusion in anemic critically ill patients >65 years?
19. What is your threshold for blood transfusion in anemic critically ill patients with a hematologic malignancy?
20. What is your threshold for blood transfusion in anemic critically ill oncology patients?
21. Do you check hemoglobin levels after transfusion of one unit red cell concentrates before transfusing a second unit in non-bleeding critically ill patients?
  - a. Always
  - b. Most of the time
  - c. Sometimes
  - d. Never
22. Do you also use physiological transfusion triggers (e.g. tachycardia) in addition to a hemoglobin threshold?
  - a. Always
  - b. Often
  - c. Sometimes
  - d. Never
23. Which physiological transfusion triggers do you use in non-bleeding patients? (multiple answers possible)
  - a. Tachycardia
  - b. Hypotension
  - c. Arrhythmia
  - d. Significant ECG changes
  - e. SvO<sub>2</sub> (mixed venous saturation of oxygen) < 65 %
  - f. ScvO<sub>2</sub> (central venous oxygen saturation) < 65 %
  - g. Lactate >2 mmol/L
  - h. Acidosis
  - i. Other, please specify
24. How would you rank the following triggers of importance to you? (1 means most important)
  - a. All triggers ticked by respondent in previous question are mentioned.
25. Which of the following treatment options do you use to prevent transfusion of red

**cell concentrates in anemic critically ill patients with iron deficiency? (multiple answers possible)**

- a. Iron supplementation
- b. Erythropoietin (epo) supplementation
- c. Iron supplementation in combination with erythropoietin (epo)
- d. None of the above
- e. Other, please specify

**26. Which measures are available in your ICU to minimize the amount of red cell concentrate transfusion? (multiple answers possible)**

- a. Closed loop sampling
- b. Computer decision making program
- c. Microtube sampling
- d. None
- e. Other, please specify

## Platelets

**27. What is your threshold for prophylactic platelet transfusion in thrombocytopenic non-bleeding patients on the ICU (thus not prior to an invasive procedure)? ( $10^9$  cells/L)**

**28. What is your threshold for platelet transfusion in non-bleeding thrombocytopenic patients prior to placing a central line on the ICU? ( $10^9$  cells/L)**

**29. What is your threshold for platelet transfusion in critically ill non-bleeding thrombocytopenic patients prior to a tracheotomy? ( $10^9$  cells/L)**

**30. What is your threshold for platelet transfusion in thrombocytopenic non-bleeding critically ill patients prior to neurosurgery? ( $10^9$  cells/L)**

**31. What is your threshold for platelet transfusion in thrombocytopenic non-bleeding critically ill patients on the ICU prior to general surgery? ( $10^9$  cells/L)**

**32. Do you check thrombocyte count after transfusion of one unit thrombocyte concentrate (1 unit is approx.  $300 \times 10^9$  platelets) before transfusing a second unit in non-bleeding critically ill patients?**

- a. Always
- b. Most of the time
- c. Sometimes
- d. Never

## Plasma

**33. Which coagulation tests are available as standard care on your ICU? (multiple answers possible)**

- a. PT/INR
- b. aPTT
- c. Fibrinogen
- d. Rotational thromboelastometry (ROTEM)
- e. Thromboelastography (TEG)
- f. Other, please specify

**34. Do you check the INR after transfusion of one unit of plasma before transfusing a second unit in a non-bleeding patient with plasmatic coagulopathy ( $INR > 3.0$ ) who used vitamin K antagonists?**

- a. Always
- b. Most of the time
- c. Sometimes
- d. Never
- e. Not applicable

- 35. How do you correct a plasmatic coagulopathy (INR>3.0) prophylactically in non-bleeding patients who used vitamin K antagonists on the ICU? (multiple answers possible)**
- Vitamin K
  - Cofact (prothrombin complex)
  - Plasma
  - Other, please specify
- 36. Do you correct a plasmatic coagulopathy (INR >3) in non-bleeding critically ill patients on the ICU prior to an invasive procedure (e.g. placing a central line) who used vitamin K antagonists?**
- Always
  - Most of the time
  - Sometimes
  - Never
- 37. How do you treat plasmatic coagulopathy (INR >3.0) prior to an invasive procedure in non-bleeding patients who used vitamin K antagonists on the ICU? (multiple answers possible)**
- Vitamin K
  - Cofact (prothrombin complex)
  - Plasma
  - Other, please specify
- 38. Do you check the INR after transfusion of one unit of plasma before transfusing a second unit in a non-bleeding patient with plasmatic coagulopathy (INR >3.0) prior to an invasive procedure on the ICU who used vitamin K antagonists?**
- Always
  - Most of the time
  - Sometimes
  - Never
  - Not applicable
- 39. If you decide to transfuse a non-bleeding critically ill patient, what type of plasma do you use? (multiple answers possible)**
- Pooled plasma (e.g. Omniplasma)
  - FFP (fresh frozen plasma)
  - Other (please specify)